SOPHiA GENETICS Advances Blood Cancer Genomic Testing With New Myeloid Solutions
Targets DNA variants and RNA fusion genes for blood cancers, including challenging variants CALR, CEBPA, ASXL1, FLT3
News provided by
Share this article
BOSTON and LAUSANNE, Switzerland, June 1, 2021 /PRNewswire/
SOPHiA GENETICS, the creator of a global data-sharing network that advances data-driven medicine, today released SOPHiA DDM™ for Blood Cancers, novel blood cancer testing solutions across the entire workflow from setup, genomic testing, and in-house advanced analytics. The solutions target the most relevant DNA variants and RNA fusion genes for blood cancers, and come with SOPHiA DDM™ platform analysis, easing the identification of major biomarkers with secondary and tertiary analyses.